Presentation is loading. Please wait.

Presentation is loading. Please wait.

Methods Chapter 2 Gillian Booth, Alice YY Cheng Canadian Diabetes Association 2013 Clinical Practice Guidelines.

Published byTravis Barbery Modified over 9 years ago

Similar presentations

Presentation on theme: "Methods Chapter 2 Gillian Booth, Alice YY Cheng Canadian Diabetes Association 2013 Clinical Practice Guidelines."— Presentation transcript:

1 Methods Chapter 2 Gillian Booth, Alice YY Cheng Canadian Diabetes Association 2013 Clinical Practice Guidelines

2 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Methods – Guiding Principles Building on 2008 CPGs Rigorous, evidence-based Transparency – process, evidence that guidelines are based on and how we evaluated that evidence Fulfill criteria outlined in AGREE II instrument Harmonization with other guidelines

3 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association International Recognition of 2008 CDA CPGs

4 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Systematic review of 11 international guidelines on oral medication for T2DM Assessed for consistency with the evidence Assessed for quality – Rigor of development – Editorial independence Conducted by the Johns Hopkins University Evidence-Based Practice Center International Recognition of 2008 CDA CPGs (continued)

5 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association

6 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association The Process 1.Develop clinical questions 2.Centralized literature search (X3) 3.Review of literature search 4.Write preamble and recommendations 5.Every recommendation reviewed and approved by 100% consensus of Steering Committee

7 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association The Process (continued) 6.External Review (national, international) 7.Independent Methods Review 8.Final approval of Steering Committee 9.Publication 10.Dissemination and Implementation

8 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Identifying Articles Identifying clinically important questions – Treatment or prevention – Diagnosis – Prognosis Centralized literature search – Systematically conducted lit searches – Known articles – Manual search of listed citations from articles

9 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Rating the Evidence Highest available level of evidence Relevant studies Formally assign each a level of evidence

10 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Same standardized approach as in 2008 Set of ‘rules’ to rate studies of a certain type (prevention/treatment, diagnosis, prognosis) Rating depends on study design plus strengths and weaknesses of the study Rating the Evidence (continued)

11 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Formulating a Recommendation 1) Recommendation What the evidence says 2) Grade What the highest level of evidence is 3) Reference(s) Study which provides the highest level of evidence

12 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Grading Recommendations Grade Best Evidence ALevel 1 BLevel 2 CLevel 3 DLevel 4 High level RCT(s) or systematic review / meta-analysis of RCTs RCT(s) or systematic review/meta-analysis Cohort studies Case control studies, case series

13 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Grading Recommendations (continued) Grade Level of confidence AHigher B C DLower

14 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Scope and Purpose Stakeholder involvement Rigour of development Applicability Editorial independence AGREE II

15 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association AGREE II Criteria

16 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association AGREE II Criteria (continued)

17 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association AGREE II Criteria (continued)

18 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association AGREE II Criteria (continued)

19 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association AGREE II Criteria (continued)

20 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association AGREE II Criteria (continued)

21 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Independent Methods Review Process More than 200 articles 85 recommendations 27 chapters 17 hours of meeting time 10 hour face to face meeting 2 - 3 hour teleconferences x 3 2013

22 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Gillian Booth (Chair) University of Toronto Doreen Rabi University of Calgary Dereck Hunt McMaster University Charlotte McDonald University of Western Ontario Valerie Palda University of Toronto Sonia Butalia University of Calgary 2013 Independent Methods Review Committee

23 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Changes to Methods in 2013 Multiple literature searches throughout period Evidence resource persons as chapter authors Publishing evidence-based worksheets Committee struck to consider how to incorporate cost and/or cost-effectiveness into CPGs 2013

24 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Duality of Interest No employees of a pharmaceutical or device company No board membership of a pharmaceutical or device company Disclosure of duality of interest at the beginning of each steering committee meeting Duality of interest details publicly available 2013

25 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association http://www.icmje.org/ethi cal_4conflicts.html

26 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Funding Sources Canadian Diabetes Association (general funds) Unrestricted educational grants – Merck Canada Inc, Novo Nordisk Canada Inc, Eli Lilly Canada Inc, Bristol-Myers Squibb / AstraZeneca collaboration, Novartis Pharmaceuticals Canada Inc. Companies were not involved in any aspect of guideline development and did not have access to guideline meetings, guideline drafts or committee deliberations 2013

27 guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CDA Clinical Practice Guidelines http://guidelines.diabetes.cahttp://guidelines.diabetes.ca – for professionals 1-800-BANTING (226-8464) http://diabetes.ca http://diabetes.ca – for patients

Download ppt "Methods Chapter 2 Gillian Booth, Alice YY Cheng Canadian Diabetes Association 2013 Clinical Practice Guidelines."

Similar presentations

Evidence-based Dental Practice Developing guidelines or clinical recommendations Slide #1 This lecture follows the previous online lecture on evidence.

Evidence-based Dental Practice Developing guidelines or clinical recommendations Slide #1 This lecture follows the previous online lecture on evidence.
Participation Requirements for a Guideline Panel Member.

Participation Requirements for a Guideline Panel Member.
Participation Requirements for a Guideline Panel Co-Chair.

Participation Requirements for a Guideline Panel Co-Chair.
Participation Requirements for a Patient Representative.

Participation Requirements for a Patient Representative.
Critical Appraisal of Clinical Practice Guidelines November 6, 2012 Mary H. Palmer, PhD, RN,C Helen W. & Thomas L. Umphlet Professor in Aging University.

Critical Appraisal of Clinical Practice Guidelines November 6, 2012 Mary H. Palmer, PhD, RN,C Helen W. & Thomas L. Umphlet Professor in Aging University.
April 2009 Netta Conyers-Haynes, Principal Consultant, Communications Kaiser Permanente National Guideline Program Implications of IOM SR Standards Wiley.

April 2009 Netta Conyers-Haynes, Principal Consultant, Communications Kaiser Permanente National Guideline Program Implications of IOM SR Standards Wiley.
Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.

Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.
Canadian Diabetes Association Clinical Practice Guidelines Natural Health Products in Type 2 Diabetes Chapter 21 Richard Nahas, Jeannette Goguen.

Canadian Diabetes Association Clinical Practice Guidelines Natural Health Products in Type 2 Diabetes Chapter 21 Richard Nahas, Jeannette Goguen.
Participation Requirements for a Guideline Panel PGIN Representative.

Participation Requirements for a Guideline Panel PGIN Representative.
Utilizing Evidence Based Practice in the Acute Care Clinical Setting Brenda P. Johnson, PhD, RN Department of Nursing Southeast Missouri State University.

Utilizing Evidence Based Practice in the Acute Care Clinical Setting Brenda P. Johnson, PhD, RN Department of Nursing Southeast Missouri State University.
1 The U.S. Preventive Services Task Force: The Challenge of Transparency Dr. Albert Siu New York Academy of Medicine.

1 The U.S. Preventive Services Task Force: The Challenge of Transparency Dr. Albert Siu New York Academy of Medicine.
Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,

Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,
Evidence for ‘excellence in care’

Evidence for ‘excellence in care’
Critical Appraisal Dr Samira Alsenany Dr SA 2012 Dr Samira alsenany.

Critical Appraisal Dr Samira Alsenany Dr SA 2012 Dr Samira alsenany.
Evidenced Based Practice; Systematic Reviews; Critiquing Research

Evidenced Based Practice; Systematic Reviews; Critiquing Research
(HINARI) PubMed Conduct systematic reviews of the literature Limit to specific populations & publication types Utilize EBM built-in filtersbuilt-in filters.

(HINARI) PubMed Conduct systematic reviews of the literature Limit to specific populations & publication types Utilize EBM built-in filtersbuilt-in filters.
Diabetes.ca | 1-800-BANTING (226-8464) 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada Canadian Diabetes Association.

Diabetes.ca | BANTING ( ) 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada Canadian Diabetes Association.
Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine.

Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine.
Chapter 7. Getting Closer: Grading the Literature and Evaluating the Strength of the Evidence.

Chapter 7. Getting Closer: Grading the Literature and Evaluating the Strength of the Evidence.
The American Society of Transplantation (AST) Guideline Development Process.

The American Society of Transplantation (AST) Guideline Development Process.

Similar presentations

Ads by Google